Metylfenidat Amdipharm

Methylphenidate, the active ingredient in Metylfenidat Amdipharm, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults. It is indicated for patients diagnosed with these conditions and is administered under medical supervision.

GNH USA supplies Metylfenidat Amdipharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU pharmaceutical standards and is distributed under strict quality controls.

Methylphenidate is a central nervous system stimulant used in the management of neurodevelopmental and sleep‑wake disorders.

- Attention Deficit Hyperactivity Disorder (ADHD): improves attention, reduces hyperactivity and impulsivity. - Narcolepsy: decreases excessive daytime sleepiness and reduces cataplexy episodes.

Methylphenidate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate pain. - Stomach pain: abdominal discomfort. - Nausea: feeling of sickness. - Increased heart rate: tachycardia.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, arrhythmia, or myocardial infarction. - Psychosis: hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Priapism: prolonged painful erection. - Growth suppression: reduced growth velocity in children. - Suicidal thoughts: emergence of suicidal ideation or behavior.

Before prescribing methylphenidate, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate blood pressure and heart rate. - Psychiatric history: screen for anxiety, bipolar disorder, or psychosis. - Growth monitoring: regularly assess height and weight in pediatric patients. - Drug interactions: avoid concurrent use with monoamine oxidase inhibitors. - Hepatic function: adjust dosing in patients with severe liver impairment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Methylphenidate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Certain antihypertensives (e.g., alpha‑agonists): may cause excessive blood pressure changes. - Seizure‑threshold‑lowering drugs: increase risk of seizures.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate levels. - Antihistamines: can enhance sedation or cardiovascular effects. - Antacids: may affect absorption. - Alcohol: can exacerbate central nervous system stimulation. - Nicotine: may alter drug metabolism.